Xerostomia (dry mouth) is a symptom of radiation-induced therapy or caused due to a side-effect of therapeutic medicines. The symptom is also seen in Sjögren’s syndrome, an autoimmune disease known to affect nearly 4 million in the United States. The absence of saliva causes difficulty in chewing and swallowing food. If left untreated, it can lead to oral health problems and bad odor. It can be treated with salivary substitutes or dentist-recommended medicine to counter the effects of the symptom.
Palliative Measures
Types of products used in treating dry mouth are dentifrices, salivary substitutes, and salivary stimulants. The dentifrices segment accounted for a large revenue share in 2016 owing to availability and affordable prices of teeth cleansing agents. Emphasis on oral hygiene and commercialization of toothpastes are factors that can lead to high adoption of dentifrices by 2025. For instance, the Biotène range of products by GlaxoSmithKline can preserve oral hygiene of patients.
The salivary stimulants segment is expected to display robust growth from 2014 to 2025 due to presence of various stimulants such as lozenges and mints. The advances in stimulants to prevent bacterial growth and bad odor are projected to increase the demand for this segment. For instance, TheraBreath Dry Mouth Oral Rinse launched by TheraBreath in April 2017 can treat the symptom by producing saliva with the help of moisturizing enzymes. Patients above the age of 60 that suffer from the symptom on account of taking various medicines can find relief.
Market Outlook
The global xerostomia (dry mouth) therapeutics market is predicted to be worth USD 796.1 million by 2025, according to a report by Grand View Research, Inc. It is expected to exhibit a 3.2% CAGR from 2017 to 2025 owing to various awareness programs highlighting the seriousness of the disease. Availability of cost-effective drugs and prescriptions may augment market demand over the forecast period (2014-2025). Key market players include Acacia Pharma; Lupin Pharmaceuticals, Inc.; Hikma Pharmaceuticals LLC; and GlaxoSmithKline plc.
In-Depth Research Report On Xerostomia (Dry Mouth) Therapeutics Market :
No comments:
Post a Comment